Skip to content

Are Solitary Fibrous Tumors Hereditary? Causes & Risks

Published: | Updated:

Solitary fibrous tumors (SFTs) are not hereditary and are not caused by lifestyle or environmental factors. You cannot pass them to your children. Instead, they are almost always caused by a random, spontaneous genetic event in a single cell known as the NAB2-STAT6 gene fusion.

Key Takeaways

  • Solitary fibrous tumors are not hereditary and cannot be passed down to your children.
  • There are no known lifestyle or environmental risk factors that cause an SFT to develop.
  • SFTs are almost always caused by a random, spontaneous genetic event called the NAB2-STAT6 gene fusion.
  • The NAB2-STAT6 fusion is a somatic mutation, meaning it occurs exclusively within the tumor cells and not in your reproductive cells.
  • Doctors may test the tumor for additional acquired mutations like TERT or TP53 to predict its behavior and guide your monitoring plan.

When you are diagnosed with a solitary fibrous tumor (SFT)—a rare, often slow-growing tumor that develops in the body’s connective tissues—it is completely normal to ask two immediate questions: “Did I do something to cause this?” and “Will I pass this to my children?”

The short answer to both questions is no. Solitary fibrous tumors are not hereditary, and there are no known lifestyle or environmental factors that cause them [1][2]. You did not cause your tumor, and you cannot pass it on to your family [3][4].

Understanding the True Cause: The NAB2-STAT6 Gene Fusion

Instead of being caused by outside factors or inherited genes, solitary fibrous tumors are almost always caused by a spontaneous genetic event within a single cell [5]. This event is called the NAB2-STAT6 gene fusion [1][6].

To understand how this works, it helps to know the difference between the two main types of genetic mutations:

  • Germline mutations (Inherited): These are genetic changes present in your DNA from birth, inherited from your parents. They exist in every cell of your body and can be passed on to your children.
  • Somatic mutations (Acquired): These are genetic changes that happen randomly in a specific cell during your lifetime [5][7]. They are not passed down from your parents, and you cannot pass them to your children [3].

The NAB2-STAT6 gene fusion is a somatic mutation [5][3]. It occurs when two normal genes (NAB2 and STAT6), which usually help regulate cell growth and function, mistakenly merge together [8]. This creates a new, abnormal gene that tells the cell to multiply uncontrollably, leading to the formation of a tumor [9][10]. Because this error only happens in the tumor cells, your reproductive cells (sperm or eggs) are completely unaffected [3].

What About Lifestyle and Environmental Risk Factors?

Many common cancers are linked to lifestyle choices or environmental exposures, such as smoking, alcohol consumption, diet, or radiation. However, solitary fibrous tumors are categorized as sporadic tumors, meaning they occur randomly and unexpectedly without a known external trigger [2][4].

Because SFTs are extremely rare, there are no known lifestyle or environmental risk factors, and there is no evidence linking them to:

  • Diet or nutrition
  • Exercise habits
  • Stress or emotional trauma
  • Smoking or alcohol use
  • Exposure to chemicals or radiation

There is simply nothing you could have done differently to prevent a solitary fibrous tumor from developing [11][2].

Are There Other Genetic Factors?

While the NAB2-STAT6 fusion is the primary driver of these tumors, doctors sometimes use Next-Generation Sequencing (NGS)—advanced testing that looks closely at the tumor’s DNA—to check for additional somatic mutations, such as TERT promoter or TP53 mutations [12][13]. You might see these terms on your pathology report.

Like the initial fusion, these are acquired (not inherited) mutations that exist exclusively within the tumor. Doctors look for these specific changes because they can help predict whether the tumor is likely to behave more aggressively—meaning it might have a higher chance of growing faster or returning after surgery [14][15]. It is important to know that these extra mutations are less common, but identifying them helps your care team tailor a specific treatment and monitoring plan for you.

Letting Go of Guilt

A diagnosis of a rare disease can bring a heavy emotional burden. Many patients spend hours retracing their steps, wondering if a past choice led to their illness. When it comes to solitary fibrous tumors, the science is clear: this was a random biological accident at the cellular level [5][1]. Understanding this can often provide a crucial sense of relief. You can let go of unnecessary guilt or worry about your family’s health, and instead focus your energy on working with your medical team on the next steps of your journey, whether that involves surgery, treatment, or active monitoring.

Frequently Asked Questions

Are solitary fibrous tumors hereditary?
No, solitary fibrous tumors are not hereditary. They are caused by a random genetic mutation called a somatic mutation that happens in a single cell during your lifetime. Because this only occurs in the tumor cells, it cannot be passed down to your children.
Did my lifestyle choices cause my solitary fibrous tumor?
There are no known lifestyle or environmental factors that cause a solitary fibrous tumor. Things like diet, exercise habits, stress, smoking, and exposure to chemicals do not cause this rare tumor to develop.
What is the NAB2-STAT6 gene fusion?
The NAB2-STAT6 gene fusion is a random biological event where two normal genes mistakenly merge together. This creates an abnormal gene that tells a cell to multiply uncontrollably, which leads to the formation of a solitary fibrous tumor.
Why do doctors test solitary fibrous tumors for TERT or TP53 mutations?
Doctors use advanced testing to check for TERT or TP53 mutations because they can help predict if the tumor is likely to grow faster or return after surgery. Knowing this helps your medical team create a personalized treatment and monitoring plan.

Questions for Your Doctor

  • Did my pathology report confirm the presence of the NAB2-STAT6 gene fusion?
  • Has my tumor tissue been tested using Next-Generation Sequencing (NGS) for additional mutations, like TERT or TP53?
  • Given that this tumor is a sporadic, acquired event, what is the best plan for monitoring it moving forward?
  • How do the specific genetic features of my tumor influence my overall risk score and treatment options?

Questions for You

  • Have I been carrying guilt or anxiety about whether my past lifestyle choices caused this diagnosis?
  • How can I clearly communicate to my children and family members that they are not at an increased genetic risk for this tumor?
  • What forms of emotional support or counseling do I need right now to process the randomness of this rare diagnosis?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    FNA cytology of solitary fibrous tumors and the diagnostic value of STAT6 immunocytochemistry.

    Tani E, Wejde J, Åström K, et al.

    Cancer cytopathology 2018; (126(1)):36-43 doi:10.1002/cncy.21923.

    PMID: 28914981
  2. 2

    Solitary fibrous tumor of central nervous system masquerading as meninigioma: Report of a rare case.

    Kataria SP, Bhutani N, Kumar S, et al.

    International journal of surgery case reports 2019; (54()):10-14 doi:10.1016/j.ijscr.2018.11.063.

    PMID: 30508695
  3. 3

    The Current Status of Solitary Fibrous Tumor: Diagnostic Features, Variants, and Genetics.

    Thway K, Ng W, Noujaim J, et al.

    International journal of surgical pathology 2016; (24(4)):281-92 doi:10.1177/1066896915627485.

    PMID: 26811389
  4. 4

    Exploring Solitary Fibrous Tumors at a Tertiary Cancer Center: Clinicopathological and Immunomorphologic Profile.

    Chowdhury Z, Mishrikotkar S, Nehra P, et al.

    Cureus 2024; (16(3)):e56899 doi:10.7759/cureus.56899.

    PMID: 38659562
  5. 5

    Solitary Fibrous Tumor in the Retroperitoneal Space Arising from the Diaphragm.

    Seito T, Kaneko T, Kawai T, et al.

    In vivo (Athens, Greece) 2023; (37(6)):2849-2853 doi:10.21873/invivo.13401.

    PMID: 37905637
  6. 6

    Diagnostics and Treatment of Extrameningeal Solitary Fibrous Tumors.

    Janik AM, Terlecka A, Spałek MJ, et al.

    Cancers 2023; (15(24)) doi:10.3390/cancers15245854.

    PMID: 38136399
  7. 7

    Clinicopathological and genetic heterogeneity of the head and neck solitary fibrous tumours: a comparative histological, immunohistochemical and molecular study of 36 cases.

    Kao YC, Lin PC, Yen SL, et al.

    Histopathology 2016; (68(4)):492-501 doi:10.1111/his.12772.

    PMID: 26154686
  8. 8

    A rare case of a solitary fibrous tumour of bone showing NAB2-STAT6 exon 3-exon 19 fusion.

    Rekhi B, Bapat P, Tripathi P, et al.

    Histopathology 2018; (73(4)):708-711 doi:10.1111/his.13658.

    PMID: 29791018
  9. 9

    NAB2-STAT6 fusion protein mediates cell proliferation and oncogenic progression via EGR-1 regulation.

    Park YS, Kim HS, Kim JH, et al.

    Biochemical and biophysical research communications 2020; (526(2)):287-292 doi:10.1016/j.bbrc.2020.03.090.

    PMID: 32216968
  10. 10

    NAB2-STAT6 drives an EGR1-dependent neuroendocrine program in solitary fibrous tumors.

    Hill C, Indeglia A, Picone F, et al.

    eLife 2025; (13()).

    PMID: 40875449
  11. 11

    Intracranial Inflammatory Myofibroblastic Tumor: A Rare Case Report.

    Sin EG, Lee J

    Case reports in oncology 2024; (17(1)):705-711 doi:10.1159/000539718.

    PMID: 39015650
  12. 12

    Case Report: Molecular Characterization of Aggressive Malignant Retroperitoneal Solitary Fibrous Tumor: A Case Study.

    Nonaka H, Kandori S, Nitta S, et al.

    Frontiers in oncology 2021; (11()):736969 doi:10.3389/fonc.2021.736969.

    PMID: 35004271
  13. 13

    Prognostic analysis of extrameningeal solitary fibrous tumor using the modified Demicco model: a clinicopathologic study of 111 Chinese cases.

    Yao CC, Zhou J, Li X, et al.

    Frontiers in oncology 2023; (13()):1272090 doi:10.3389/fonc.2023.1272090.

    PMID: 38239634
  14. 14

    Solitary fibrous tumors: loss of chimeric protein expression and genomic instability mark dedifferentiation.

    Dagrada GP, Spagnuolo RD, Mauro V, et al.

    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2015; (28(8)):1074-83 doi:10.1038/modpathol.2015.70.

    PMID: 26022454
  15. 15

    Prognostic significance of NAB2-STAT6 fusion variants and TERT promotor mutations in solitary fibrous tumors/hemangiopericytomas of the CNS: not (yet) clear.

    Vogels R, Macagno N, Griewank K, et al.

    Acta neuropathologica 2019; (137(4)):679-682 doi:10.1007/s00401-019-01968-3.

    PMID: 30761420

This page is for informational purposes only and does not replace professional medical advice. Please consult your oncology team or a genetic counselor with specific questions about the causes and genetic features of your tumor.

Stay up to date

Get notified when new research about Solitary Fibrous Tumor (SFT) is published.

No spam. Unsubscribe anytime.